To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

NCT06344052 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: SP-002
DRUG: Vismodegib

Sponsor

Stamford Pharmaceuticals, Inc.